Recent findings indicate a potential link between the drug tadalafil, used for erectile dysfunction and enlarged prostate symptoms, and an increased risk of developing glaucoma. This condition can lead to gradual vision loss. The study analyzed health records from close to 74,000 men aged 40 and above, with lower urinary tract issues, to explore the connection between long-term tadalafil usage and glaucoma risk.

Published in the British Journal of Ophthalmology, the research compared about 37,000 men who were prescribed tadalafil with another group that did not use phosphodiesterase type 5 inhibitors, which include Cialis. Men were monitored for up to five years to identify new occurrences of glaucoma or increased eye pressure, as well as any instances of needing glaucoma treatment.

Key Findings:

• Men using tadalafil showed a 22% higher likelihood of developing glaucoma compared to non-users.
• They were also 32% more likely to experience increased eye pressure.
• There was a 33% greater chance of developing primary open-angle glaucoma, the most common form of the disease.

Dr. Valerie Kattouf, an optometrist at the Illinois Eye Institute, highlighted that glaucoma often lacks obvious symptoms in the early stages. As it advances, it can lead to a loss of peripheral vision.

For those with a family history of glaucoma, high eye pressure, or severe nearsightedness, the risk might be higher. Extended daily use of Cialis should prompt closer monitoring.

Regular comprehensive eye exams are recommended for those using tadalafil. These exams can help establish a baseline for eye health and detect any early changes indicative of glaucoma.

The research, being observational, identified a link but did not prove causation between tadalafil use and glaucoma. It did not account for changes in medication use or new health issues over time. Researchers recommend that patients, particularly those with other glaucoma risk factors, should not cease using tadalafil based on these findings alone but should engage in regular eye monitoring.

Comments from Eli Lilly, the Cialis manufacturer, and the study’s researchers have been sought by Fox News Digital.
Kelly McGreal, a production assistant at Fox News Digital, contributed to this report.